|
Strides made in the sector of cardiac disease treatment over the past
decade are attributable to preceding researches made in the sector. Clinical
research as well as pre-clinical study must be developed first in order
to enable the successful development of new treatment for coronary artery
disease. As such, CVRF focuses on invigoration of clinical research on
cardiovascular diseases, and will provide support clinical researches
in cooperation with international and multi centers. The center provides
the infrastructure to investigators who receive their primary research.
It will become the research body in Asia to establish Core Laboratories
and data management center for independent analysis of relevant data for
higher efficiency and accuracy in operations.
CVRF has provided support for a total of 19 basic and clinical researches.
In 2006, it will begin with the following 11 projects:
• |
Percutaneous treatment of long native coronary lesions
with drug-eluting stent: cypher versus taxus: LONG-DES. |
• |
Serial intravascular ultrasound findings in patients with ruptured
coronary plaques: Evidence of both plaque stabilization and lesion
progression. |
• |
Effects of atorvastatin versus rosuvastatin therapy on coronary
atherosclerotic plaque: a prospective randomized comparison trial
with intravascular ultrasound. |
• |
Evaluation of neo-endothelization at the stent overlapping segment
after kissing stenting with sirolimus-eluting stent. |
• |
Identification of patients at low risk of 6-month instent restenosis
of bare metal stenting in the real world. |
• |
Glycosylated hemoglobin level as a predictor of restenosis after
drug-eluting stent implantation in diabetes mellitus patients. |
• |
Retrospective comparison of early and mid-term outcomes after sirolimus-eluting
stent implantation versus coronary artery bypass grafting in patients
with multivessel coronary artery disease. |
• |
Tissue plasminogen activator on admission is an important predictor
for 30-day mortality in patients with acute myocardial infarction
undergoing primary angioplasty. |
• |
Korean multi-center study for stent thrombosis after drug-eluting
stent implantation: Clinical findings, outcomes and risk factors analysis. |
• |
Validation of new drug-eluting stent in a porcine coronary artery
model of resteosis. |
• |
Valsartan for suppression of plaque volume and restenosis after
paclitaxel-eluting stent |
Myeong-Ki Hong, MD, PhD
The Cardiovascular Core Laboratories at the CRCC of CVRF is an academic
cardiovascular imaging Core Lab which provides internationally recognized
expertise in an efficient and responsive environment. The Core Labs provides
the result of an unbiased interpretation about pharmaceutical or mechanical
intervention in coronary artery disease and cardiac transplant studies.
The independent processes reduce interobserver or interobserver variability
and increase the accuracy and precision of results. Also the Core Labs
will ensure the investigators are adequately trained to optimize the yield
of the imaging data and see that all regulatory requirements are in place.
It also will assist with data analysis and interpretation, presentations
to the medical community and education of the regulatory agencies about
the study results.
The IVUS Core Lab offers a non-distortion analysis and conclusion of
the data, as recorded ultrasonographically. The IVUS Core Lab contains
sophisticated computer imaging equipment and analysis workstations designed
specifically for qualitative and quantitative coronary and peripheral
ultrasound analyses. It increases accuracy and reproducibility of interpreted
results by decreasing inter-observer variability through consistent training
and systematic analytical processes. The IVUS Lab had experience in providing
intravascular ultrasound analysis for clinical studies in the area of
atheroma progression/regression, various interventional techniques, transplant
vasculopathy, quantitative IVUS analysis, plaque morphology, stent optimization,
and quantitative and qualitative analysis for predicting the outcome of
percutaneous coronary intervention.
The QCA Core Lab exploits and adjusts catheterization and other procedure
imaging protocols for each clinical trial and project. It achieves perfect
and elaborate analysis of data for patients and clinical trial research’s
accomplishment based on ceaseless attempt and mind aim at perfection.
The Core Lab has experience in providing analysis for clinical studies
of percutaneous coronary intervention with stent, direct angioplasty,
new coronary devices, and interventions with concomitant drug therapy.
Importantly, the Core Lab is dedicated to the collection of data on TIMI
grading and frame counting, morphology assessments for AHA/ACC lesion
classification, quantitative coronary angiography (QCA), including minimum
lesion diameter, maximum percent diameter and area stenosis, normal (reference)
vessel diameters and lesion length, left-ventricular ejection fraction
and regional wall motion results, and ventricular volume indices.
Young-Hak Kim, MD, PhD
The CRCC develops and plans a model for success and evaluate the feasibility
of clinical researches working with international multi centers. Also,
we analyze the characteristics and pattern of patients with cardiovascular
disease and direct the tool of clinical research. Exact and efficient
directing is the most of basic and essential steps for the derivation
of useful data.
A goal of data management is to provide the essential information to
prevent and control cardiovascular disease through analysis without bias.
We specialize in the data collection and processing, outcome reporting
of large data sets typically associated with healthcare eligibility, claims
processing, and performance measurement. These data sets are used to provide
meaningful reports that aid management in day-to-day operations. In addition,
we have the capability to perform more detailed analysis and research
on data in order to better understand the complexities of service delivery
systems. |